Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): A randomised, double-blind, parallel-group trial

Míreanna comhchosúla

• Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial.
  de réir: Bousser, MG, et al.
  Foilsithe / Cruthaithe: (2011)
• Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study.
  de réir: Bousser, MG, et al.
  Foilsithe / Cruthaithe: (2009)
• The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population.
  de réir: Bousser, MG, et al.
  Foilsithe / Cruthaithe: (2009)
• Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population.
  de réir: Fox, K, et al.
  Foilsithe / Cruthaithe: (2013)
• Heart rate is a prognostic risk factor for myocardial infarction: A post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history of ischemic strOke or tRansient ischeMic attack) study population
  de réir: Fox, K, et al.
  Foilsithe / Cruthaithe: (2013)